1460776921-995e5995-94b1-4fee-b8fa-4bde24d0a637

1. An active medical device, comprising:
means for detecting a respiratory activity of a patient and producing a signal corresponding to said detected respiratory activity;
means for determining a state of activity of the patient comprising means for acquiring an activity parameter, means for comparing said activity parameter to a predetermined criteria, and means for determining that said state is a sleep state on satisfaction of said predetermined criteria,
means for analyzing the detecting means signal comprising means for identifying a respiratory pause and for determining a duration of said detected respiratory pause, and means for producing an indicating signal of sleep apnea in response to an identified respiratory pause having a duration longer than a first predetermined duration during a determined sleep state;
wherein the analyzing means further comprises means for inhibiting the production of the indicating signal in response to said respiratory pause duration being longer than a second predetermined duration.
2. The device of claim 1, wherein said second predetermined duration is at least one minute.
3. The device of claim 1, wherein said device is an implantable medical device and further comprises means for treating a sleep apnea syndrome by delivering an electro-cardiac stimulation in response to said indicating signal, and means for inhibiting said electro-cardiac stimulation treating means from delivering a stimulation in response to the detected respiratory pause being longer than said second predetermined duration.
4. An active medical device, comprising:
a respiratory activity monitor having an output signal corresponding to a patient’s respiratory activity;
a patient state detector including an activity sensor having an output corresponding to a patient activity state, said detector including a predetermined criteria corresponding to a sleep state, and said output signal having a sleep state output in response to said patient activity signal satisfying said predetermined criteria;
a controller able to analyze the respiratory output signal and said state detector wherein the controller analyzes the respiratory output signal and identifies a respiratory pause therein and a duration of said detected respiratory pause, and produces an indicating signal of sleep apnea in response to an identified respiratory pause having a duration longer than a first predetermined duration during a determined sleep state;
wherein the controller operates to inhibit the production of the indicating signal in response to said respiratory pause duration being longer than a second predetermined duration.
5. The device of claim 4, wherein said second predetermined duration is at least one minute.
6. The device of claim 4, wherein said device is an implantable medical device and further comprises means for treating a sleep apnea syndrome by delivering an electro-cardiac stimulation in response to said indicating signal, and means for inhibiting said electro-cardiac stimulation treating means from delivering a stimulation in response to the detected respiratory pause being longer than said second predetermined duration.
7. An active medical device, comprising:
a respiratory activity monitor having an output signal corresponding to a patient’s respiratory activity;
a patient state detector including an activity sensor having an output corresponding to a patient activity state, said detector including a predetermined criteria corresponding to a sleep state, and said output signal having a sleep state output in response to said patient activity signal satisfying said predetermined criteria;
a controller able to analyze the respiratory output signal and said state detector wherein the controller analyzes the respiratory output signal and identifies a respiratory pause therein and a duration of said detected respiratory pause, and produces an indicating signal of sleep apnea in response to an identified respiratory pause having a duration longer than a first predetermined duration during a determined sleep state;
wherein the controller operates to disregard the indicating signal in response to said respiratory pause duration being longer than a second predetermined duration.
8. The device of claim 7, wherein said second predetermined duration is at least one minute.
9. The device of claim 7, wherein said device is an implantable medical device and further comprises means for treating a sleep apnea syndrome by delivering an electro-cardiac stimulation in response to said indicating signal, and means for inhibiting said electro-cardiac stimulation treating means from delivering a stimulation in response to the detected respiratory pause being longer than said second predetermined duration.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A compound of Formula I, including pharmaceutically acceptable salts thereof,
A is phenyl or heteroaryl; wherein said heteroaryl is a monocyclic ring and is comprised of 5 to 6 atoms selected from the group consisting of C, N, NR9, O, and S; and wherein each ring of said phenyl and heteroaryl is optionally substituted with one bromo, fluoro, or methyl group;
W is O;
T is
Z1 is CR1 or N;
Z2 is CR2 or N;
Z3 is CR3 or N;
Z4 is CR4 or N;
Z5 is CR5 or N;
Z6 is CR6 or N;
Z7 is CR7 or N;
Z8 is CR8 or N;
wherein one and not more than one of Z1 through Z8 is N;
R1, R2, R3, R4, R5, R6, R7 and R8 are each independently selected from the group consisting of a bond, hydrogen, halogen, cyano, nitro, X\u2032R24, C1-6alkyl, C3-7cycloalkyl, C2-6alkenyl, C4-7cycloalkenyl, C2-6alkynyl, aryl, heteroaryl, heteroalicyclic, C(O)NR28R29, COR25 and CO2R25; wherein said C1-6alkyl, C3-7cycloalkyl, C2-6alkenyl, C4-7cycloalkenyl, C2-6alkynyl, aryl, heteroaryl, and heteroalicyclic are optionally substituted with one to nine same or different halogens or from one to five same or different substituents selected from the substituents comprising group F;
m is 1; p is 1;
F is selected from the group consisting of C1-6alkyl, hydroxy, C1-6alkoxy, cyano, halogen, benzyl, N-amido, NR30R31, C1-6alkylC(O)NR30R31, C(O)NR30R31, COOR32 and C1-6alkylCOOR32;
R9 is selected from the group consisting of hydrogen, hydroxy, C1-6alkyl, C1-6alkoxy, cyano, and fluoro;
R11, R12, R13, R14, R15, R16, R17 and R18 are each independently selected from the group consisting of hydrogen and methyl;
X\u2032 is selected from the group consisting of NR10, O, and S;
R24 is hydrogen or C1-6alkyl;
R25 is selected from the group consisting of hydrogen, C1-6alkyl, C3-7cycloalkyl, aryl and heteroaryl;
R28 and R29 are each independently selected from the group consisting of hydrogen, SO2C1-6alkyl, C1-6alkyl, C3-7cycloalkyl, aryl, heteroaryl, and heteroalicyclic wherein said C1-6alkyl, C3-7cycloalkyl, aryl, heteroaryl, and heteroalicyclic are optionally substituted with one to nine same or different halogens or C1-6alkyl groups;
R30 and R31 are each independently selected from the group consisting of hydrogen, C1-6alkyl, C3-7cycloalkyl, aryl, wherein said C1-6alkyl, C3-7cycloalkyl, and aryl are optionally substituted with one to nine same or different halogens;
R32 is selected from the group consisting of hydrogen, C1-6alkyl, and C3-7cycloalkyl;
provided that at any given time only one of the members selected from the group consisting of R1, R2, R3, R4, R5, R6, R7 and R8 is a bond, and further provided that said bond is the point of attachment to the adjacent carbon atom in the compound of Formula I.
2. A compound of claim 1, including pharmaceutically acceptable salts thereof, wherein:
Q is:
and R6 is a bond for point of attachment.
3. A compound of claim 2, including pharmaceutically acceptable salts thereof, wherein:
Q is
and R5 is a bond for point of attachment.
4. A compound of claim 2, including pharmaceutically acceptable salts thereof, wherein:
Q is
and R6 is a bond for point of attachment.
5. A pharmaceutical composition which comprises an antiviral effective amount of a compound of Formula I, including pharmaceutically acceptable salts thereof, as claimed in claim 1, and on or more pharmaceutically acceptable carriers, excipients or diluents.
6. A method for treating a mammal infected with HIV, comprising administering to said mammal an antiviral effective amount of a compound of Formula I, including pharmaceutically acceptable salts thereof, as claimed in claim 1, and one or more pharmaceutically acceptable carriers, excipients or diluents.